Stem Cells Therapy in Advanced Heart Failure

Intra Cardiac Autologous Stem Cells Infusion May Improve Clinical Outcomes in Failing Heart Subjects Refractory to Maximal Drug Therapy and Internal Cardioverter With a Defibrillator (ICD) Recipients

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02871466

Enrollment

Registered

2016-08-18

Start date

2010-01-31

Completion date

2022-07-31

Last updated

2020-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congestive Heart Failure

Brief summary

stem cells therapy may be a choice therapy for advanced heart failure patients refractory to medical therapy, internal cardiovertor with a defibrillator (ICD) recipients, and a previous history of myocardial infarction and coronary artery revascularization. These patients, without indication to receive a cardiac resynchronization therapy (CRT), may have a worsening of heart failure, and symptoms of coronary artery disease. In this study we have evaluated in consecutive 30 selected patients the amelioration in failing heart NYHA class, hospitalization rate, echocardiographic left ventricle functionality, and associated to reduction of angina after a treatment with stem cells intra thoracic infusion.

Interventions

DRUGstem cells infusion

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* heart failure post coronary artery disease, refractory to maximal medical therapy, previous coronary artery surgical revascularization.

Exclusion criteria

* inflammatory chronic diseases, neoplastic diseases.

Design outcomes

Primary

Measure	Time frame
NYHA class improvement	12 months
reduction in hospitalization rate	12 months
reduction in angor symptoms	12 months

Countries

Italy

Contacts

Primary ContactRaffaele Marfella, MD, PhD

raffaele.marfella@unicampania.it00390815566101

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026